Thomas F Jaki

List of Publications by Year
in descending order

151	21,121	159358	11581
papers	citations	30	135
		h-index	g-index

165	165	165	35804
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A novel statistical test for treatment differences in clinical trials using a response‐adaptive forward‐looking Gittins Index Rule. Biometrics, 2023, 79, 86-97.	0.8	3
2	A benchmark for dose-finding studies with unknown ordering. Biostatistics, 2022, 23, 721-737.	0.9	9
3	Practical recommendations for implementing a Bayesian adaptive phase I design during a pandemic. BMC Medical Research Methodology, 2022, 22, 25.	1.4	4
4	Individual differences in the effects of the ACTION-PAC intervention: an application of personalized medicine in the prevention and treatment of obesity. Journal of Behavioral Medicine, 2022, 45, 211-226.	1.1	2
5	An order restricted multi‐arm multi‐stage clinical trial design. Statistics in Medicine, 2022, 41, 1613-1626.	0.8	4
6	A dose‐finding design for dual‐agent trials with patient‐specific doses for one agent with application to an opiate detoxification trial. Pharmaceutical Statistics, 2022, 21, 476-495.	0.7	3
7	Generalisations of a Bayesian decision-theoretic randomisation procedure and the impact of delayed responses. Computational Statistics and Data Analysis, 2022, 174, 107407.	0.7	7
8	Methods for Non-Compartmental Pharmacokinetic Analysis With Observations Below the Limit of Quantification. Statistics in Biopharmaceutical Research, 2021, 13, 59-70.	0.6	9
9	Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2021, 384, 693-704.	13.9	8,063
10	Assessing goodness‐of‐fit for evaluation of dose‐proportionality. Pharmaceutical Statistics, 2021, 20, 272-281.	0.7	3
11	Recurrent events modelling of haemophilia bleeding events. Journal of the Royal Statistical Society Series C: Applied Statistics, 2021, 70, 351-371.	0.5	0
12	Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study. International Journal of Environmental Research and Public Health, 2021, 18, 345.	1.2	8
13	Statistical consideration when adding new arms to ongoing clinical trials: the potentials and the caveats. Trials, 2021, 22, 203.	0.7	15
14	Study to evaluate the optimal dose of remifentanil required to ensure apnea during magnetic resonance imaging of the heart under general anesthesia. Paediatric Anaesthesia, 2021, 31, 548-556.	0.6	2
15	Optimizing subgroup selection in two‐stage adaptive enrichment and umbrella designs. Statistics in Medicine, 2021, 40, 2939-2956.	0.8	11
16	Applying methods for personalized medicine to the treatment of alcohol use disorder.. Journal of Consulting and Clinical Psychology, 2021, 89, 288-300.	1.6	10
17	Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. Journal of Antimicrobial Chemotherapy, 2021, 76, 3286-3295.	1.3	84
18	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498

#	Article	IF	Citations
19	Bridging across patient subgroups in phase I oncology trials that incorporate animal data. Statistical Methods in Medical Research, 2021, 30, 1057-1071.	0.7	2
20	Costs and staffing resource requirements for adaptive clinical trials: quantitative and qualitative results from the Costing Adaptive Trials project. BMC Medicine, 2021, 19, 251.	2.3	4
21	A benchmark for dose finding studies with continuous outcomes. Biostatistics, 2020, 21, 189-201.	0.9	13
22	Repeated measures regression mixture models. Behavior Research Methods, 2020, 52, 591-606.	2.3	7
23	TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 70, 2062-2072.	2.9	10
24	Improving safety of the continual reassessment method via a modified allocation rule. Statistics in Medicine, 2020, 39, 906-922.	0.8	6
25	A comparison of stochastic programming methods for portfolio level decision-making. Journal of Biopharmaceutical Statistics, 2020, 30, 405-429.	0.4	4
26	Designing and evaluating dose-escalation studies made easy: The MoDEsT web app. Clinical Trials, 2020, 17, 147-156.	0.7	6
27	Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. New England Journal of Medicine, 2020, 383, 2030-2040.	13.9	1,013
28	Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2020, 396, 1345-1352.	6.3	569
29	A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation. Clinical Trials, 2020, 17, 522-534.	0.7	3
30	Endpoints for randomized controlled clinical trials for COVID-19 treatments. Clinical Trials, 2020, 17, 472-482.	0.7	55
31	Efficient Adaptive Designs for Clinical Trials of Interventions for COVID-19. Statistics in Biopharmaceutical Research, 2020, 12, 483-497.	0.6	40
32	Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs. BMC Medicine, 2020, 18, 352.	2.3	42
33	An information theoretic approach for selecting arms in clinical trials. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2020, 82, 1223-1247.	1.1	9
34	A surface-free design for phase I dual-agent combination trials. Statistical Methods in Medical Research, 2020, 29, 3093-3109.	0.7	6
35	Using a dose-finding benchmark to quantify the loss incurred by dichotomization in Phase II dose-ranging studies. Biometrical Journal, 2020, 62, 1717-1729.	0.6	1
36	The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. Trials, 2020, 21, 528.	0.7	10

#	Article	IF	Citations
37	The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ, The, 2020, 369, m115.	3.0	57
38	AGILE-ACCORD: A Randomized, Multicentre, Seamless, Adaptive Phase I/II Platform Study to Determine the Optimal Dose, Safety and Efficacy of Multiple Candidate Agents for the Treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials, 2020, 21, 544.	0.7	23
39	A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine, 2020, 382, 1787-1799.	13.9	4,209
40	Estimation of treatment effects following a sequential trial of multiple treatments. Statistics in Medicine, 2020, 39, 1593-1609.	0.8	6
41	Exposure–response modelling approaches for determining optimal dosing rules in children. Statistical Methods in Medical Research, 2020, 29, 2583-2602.	0.7	1
42	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. New England Journal of Medicine, 2020, 382, 1366-1369.	13.9	63
43	A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports, 2020, 10, 1796.	1.6	4
44	Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial. Lancet Rheumatology, The, 2020, 2, e135-e141.	2.2	62
45	A quantitative framework to inform extrapolation decisions in children. Journal of the Royal Statistical Society Series A: Statistics in Society, 2020, 183, 515-534.	0.6	2
46	Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet, The, 2020, 395, 1569-1578.	6.3	2,875
47	A critical review of graphics for subgroup analyses in clinical trials. Pharmaceutical Statistics, 2020, 19, 541-560.	0.7	12
48	A novel measure of drug benefit–risk assessment based on Scale Loss Score. Statistical Methods in Medical Research, 2019, 28, 2738-2753.	0.7	6
49	A Bayesian model to estimate the cutoff and the clinical utility of a biomarker assay. Statistical Methods in Medical Research, 2019, 28, 2538-2556.	0.7	4
50	Instrumental Variable Estimation in Semi-Parametric Additive Hazards Models. Biometrics, 2019, 75, 110-120.	0.8	6
51	The Effects of Sample Size on the Estimation of Regression Mixture Models. Educational and Psychological Measurement, 2019, 79, 358-384.	1.2	23
52	An Information Theoretic Phase I–II Design for Molecularly Targeted Agents That Does Not Require an Assumption of Monotonicity. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 347-367.	0.5	23
53	A flexible design for advanced Phase I/II clinical trials with continuous efficacy endpoints. Biometrical Journal, 2019, 61, 1477-1492.	0.6	5
54	Subgroup analysis of treatment effects for misclassified biomarkers with time–to–event data. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 1447-1463.	0.5	2

#	Article	IF	Citations
55	How to design a dose-finding study using the continual reassessment method. BMC Medical Research Methodology, 2019, 19, 18.	1.4	56
56	A Review of Perspectives on the Use of Randomization in Phase II Oncology Trials. Journal of the National Cancer Institute, 2019, 111, 1255-1262.	3.0	35
57	Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat17(5):593â€606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873. Pharmaceutical Statistics, 2019, 18, 284-286.	0.7	1
58	Loss functions in restricted parameter spaces and their Bayesian applications. Journal of Applied Statistics, 2019, 46, 2314-2337.	0.6	4
59	Bayesian sequential integration within a preclinical pharmacokinetic and pharmacodynamic modeling framework: Lessons learned. Pharmaceutical Statistics, 2019, 18, 486-506.	0.7	4
60	Confidence regions for treatment effects in subgroups in biomarker stratified designs. Biometrical Journal, 2019, 61, 27-39.	0.6	2
61	Randomized dose-escalation designs for drug combination cancer trials with immunotherapy. Journal of Biopharmaceutical Statistics, 2019, 29, 359-377.	0.4	11
62	The *R* Package **MAMS** for Designing Multi-Arm Multi-Stage Clinical Trials. Journal of Statistical Software, 2019, 88, .	1.8	15
63	Telmisartan to reduce insulin resistance in HIV-positive individuals on combination antiretroviral therapy: the TAILoR dose-ranging Phase II RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-168.	0.9	0
64	A review of the deterministic and diffusion approximations for stochastic chemical reaction networks. Reaction Kinetics, Mechanisms and Catalysis, 2018, 123, 289-312.	0.8	12
65	Optimal Designs for Non-Compartmental Analysis of Pharmacokinetic Studies. Statistics in Biopharmaceutical Research, 2018, 10, 255-263.	0.6	4
66	Adaptive designs in clinical trials: why use them, and how to run and report them. BMC Medicine, 2018, 16, 29.	2.3	398
67	Extrapolation of efficacy and other data to support the development of new medicines for children: A systematic review of methods. Statistical Methods in Medical Research, 2018, 27, 398-413.	0.7	33
68	Identification of predicted individual treatment effects in randomized clinical trials. Statistical Methods in Medical Research, 2018, 27, 142-157.	0.7	43
69	A review of statistical updating methods for clinical prediction models. Statistical Methods in Medical Research, 2018, 27, 185-197.	0.7	91
70	An evaluation of the bootstrap for model validation in mixture models. Communications in Statistics Part B: Simulation and Computation, 2018, 47, 1028-1038.	0.6	10
71	A framework for prospectively defining progression rules for internal pilot studies monitoring recruitment. Statistical Methods in Medical Research, 2018, 27, 3612-3627.	0.7	11
72	Model selection based on combined penalties for biomarker identification. Journal of Biopharmaceutical Statistics, 2018, 28, 735-749.	0.4	2

#	Article	IF	Citations
73	Multi-arm multi-stage trials can improve the efficiency of finding effective treatments for stroke: a case study. BMC Cardiovascular Disorders, 2018, 18, 215.	0.7	9
74	Development process of a consensus-driven CONSORT extension for randomised trials using an adaptive design. BMC Medicine, 2018, 16, 210.	2.3	28
75	Performance of different clinical trial designs to evaluate treatments during an epidemic. PLoS ONE, 2018, 13, e0203387.	1.1	12
76	Subgroup identification in clinical trials via the predicted individual treatment effect. PLoS ONE, 2018, 13, e0205971.	1.1	26
77	An alternative method to analyse the biomarker€strategy design. Statistics in Medicine, 2018, 37, 4636-4651.	0.8	4
78	A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics, 2018, 17, 593-606.	0.7	6
79	Design and estimation in clinical trials with subpopulation selection. Statistics in Medicine, 2018, 37, 4335-4352.	0.8	18
80	Dose€escalation strategies which use subgroup information. Pharmaceutical Statistics, 2018, 17, 414-436.	0.7	10
81	A DIAGNOSTIC TOOL FOR CHECKING ASSUMPTIONS OF REGRESSION MIXTURE MODELS. JP Journal of Biostatistics, 2018, 15, 1-20.	0.0	4
82	Asymmetric inner wedge group sequential tests with applications to verifying whether effective drug concentrations are similar in adults and children. Statistics in Medicine, 2017, 36, 426-441.	0.8	0
83	Estimation in multi-arm two-stage trials with treatment selection and time-to-event endpoint. Statistics in Medicine, 2017, 36, 3137-3153.	0.8	13
84	Simultaneous confidence regions for multivariate bioequivalence. Statistics in Medicine, 2017, 36, 4585-4603.	0.8	14
85	Bayesian adaptive dose€escalation designs for simultaneously estimating the optimal and maximum safe dose based on safety and efficacy. Pharmaceutical Statistics, 2017, 16, 396-413.	0.7	12
86	Comparing sampling methods for pharmacokinetic studies using model averaged derived parameters. Statistics in Medicine, 2017, 36, 4301-4315.	0.8	1
87	Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments. Statistics in Medicine, 2017, 36, 563-580.	0.8	15
88	A Bayesian adaptive design for clinical trials in rare diseases. Computational Statistics and Data Analysis, 2017, 113, 136-153.	0.7	46
89	Tilting the lasso by knowledge-based post-processing. BMC Bioinformatics, 2016, 17, 344.	1.2	6
90	Designing multi€arm multi€stage clinical trials using a risk€benefit criterion for treatment selection. Statistics in Medicine, 2016, 35, 522-533.	0.8	7

#	Article	IF	Citations
91	Modeling Predictors of Latent Classes in Regression Mixture Models. Structural Equation Modeling, 2016, 23, 601-614.	2.4	56
92	A false sense of security? Can tiered approach be trusted to accurately classify immunogenicity samples?. Journal of Pharmaceutical and Biomedical Analysis, 2016, 128, 166-173.	1.4	6
93	Why are two mistakes not worse than one? A proposal for controlling the expected number of false claims. Pharmaceutical Statistics, 2016, 15, 362-367.	0.7	3
94	Clinical Drug Development in Epilepsy Revisited: A Proposal for a New Paradigm Streamlined Using Extrapolation. CNS Drugs, 2016, 30, 1011-1017.	2.7	17
95	Understanding clinical prediction models as 'innovations': a mixed methods study in UK family practice. BMC Medical Informatics and Decision Making, 2016, 16, 106.	1.5	14
96	Assessing the feasibility of injectable growth-promoting therapy in Crohn's disease. Pilot and Feasibility Studies, 2016, 2, 71.	0.5	2
97	Some recommendations for multi-arm multi-stage trials. Statistical Methods in Medical Research, 2016, 25, 716-727.	0.7	67
98	Impact of an equality constraint on the class-specific residual variances in regression mixtures: A Monte Carlo simulation study. Behavior Research Methods, 2016, 48, 813-826.	2.3	15
99	Using Multilevel Regression Mixture Models to Identify Level-1 Heterogeneity in Level-2 Effects. Structural Equation Modeling, 2016, 23, 259-269.	2.4	6
100	A review of statistical designs for improving the efficiency of phase II studies in oncology. Statistical Methods in Medical Research, 2016, 25, 1010-1021.	0.7	8
101	Sample Size Reassessment and Hypothesis Testing in Adaptive Survival Trials. PLoS ONE, 2016, 11, e0146465.	1.1	32
102	Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy. BMJ Open, 2015, 5, e009566.	0.8	9
103	Multi-arm clinical trials with treatment selection: what can be gained and at what price?. Clinical Investigation, 2015, 5, 393-399.	0.0	26
104	A practical design for a dual-agent dose-escalation trial that incorporates pharmacokinetic data. Statistics in Medicine, 2015, 34, 2138-2164.	0.8	7
105	Bayesian adaptive dose-escalation procedures for binary and continuous responses utilizing a gain function. Pharmaceutical Statistics, 2015, 14, 479-487.	0.7	14
106	Evaluating Differential Effects Using Regression Interactions and Regression Mixture Models. Educational and Psychological Measurement, 2015, 75, 677-714.	1.2	28
107	Adaptive clinical trials in tuberculosis: applications, challenges and solutions. International Journal of Tuberculosis and Lung Disease, 2015, 19, 626-634.	0.6	23
108	Statistical approaches for the determination of cut points in anti-drug antibody bioassays. Journal of Immunological Methods, 2015, 418, 84-100.	0.6	19

#	Article	IF	Citations
109	Flexible sequential designs for multiâ€arm clinical trials. Statistics in Medicine, 2014, 33, 3269-3279.	0.8	27
110	A hybrid method to estimate the minimum effective dose for monotone and nonâ€monotone doseâ€"response relationships. Biometrics, 2014, 70, 103-109.	0.8	4
111	A comparison of methods for classifying samples as truly specific with confirmatory immunoassays. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 27-35.	1.4	4
112	Designing Multi-arm Multi-stage Clinical Studies. , 2014, , 51-69.		7
113	Statistical evaluation of toxicological assays: Dunnett or Williams testâ€"take both. Archives of Toxicology, 2013, 87, 1901-1910.	1.9	21
114	Principles of dose finding studies in cancer: a comparison of trial designs. Cancer Chemotherapy and Pharmacology, 2013, 71, 1107-1114.	1.1	48
115	Planning multiâ€arm screening studies within the context of a drug developmentâ€‰program. Statistics in Medicine, 2013, 32, 3424-3435.	0.8	13
116	Authors' reply to Comments on â€˜Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designsâ€™. Statistics in Medicine, 2013, 32, 5487-5488.	0.8	0
117	Designing exploratory cancer trials using change in tumour size as primary endpoint. Statistics in Medicine, 2013, 32, 2544-2554.	0.8	14
118	Differential Effects of Parental Controls on Adolescent Substance Use: For Whom is the Family Most Important?. Journal of Quantitative Criminology, 2013, 29, 347-368.	2.0	44
119	Uptake of novel statistical methods for early-phase clinical studies in the UK public sector. Clinical Trials, 2013, 10, 344-346.	0.7	35
120	Simultaneous confidence intervals that are compatible with closed testing in adaptive designs. Biometrika, 2013, 100, 985-996.	1.3	23
121	Finite Mixtures for Simultaneously Modeling Differential Effects and Nonnormal Distributions. Multivariate Behavioral Research, 2013, 48, 816-844.	1.8	10
122	Considerations on covariates and endpoints in multiâ€arm multiâ€stage clinical trials selecting all promisingâ€‰treatments. Statistics in Medicine, 2013, 32, 1150-1163.	0.8	18
123	Analysing malaria drug trials on a perâ€individual or perâ€clone basis: aâ€‰comparison of methods. Statistics in Medicine, 2013, 32, 3020-3038.	0.8	16
124	Estimation in AB/BA crossover trials with application to bioequivalence studies with incomplete and complete data designs. Statistics in Medicine, 2013, 32, 5469-5483.	0.8	6
125	Using regression mixture models with non-normal data: examining an ordered polytomous approach. Journal of Statistical Computation and Simulation, 2013, 83, 759-772.	0.7	18
126	Recovering Independent Associations in Genetics: A Comparison. Journal of Computational Biology, 2012, 19, 978-987.	0.8	1

#	Article	IF	Citations
127	A generalized Dunnett test for multi-arm multi-stage clinical studies with treatment selection. Biometrika, 2012, 99, 494-501.	1.3	109
128	Not Quite Normal: Consequences of Violating the Assumption of Normality in Regression Mixture Models. Structural Equation Modeling, 2012, 19, 227-249.	2.4	32
129	Non‐compartmental estimation of pharmacokinetic parameters for flexible sampling designs. Statistics in Medicine, 2012, 31, 1059-1073.	0.8	21
130	A novel Phase I/IIa design for early phase oncology studies and its application in the evaluation of MK-0752 in pancreatic cancer. Statistics in Medicine, 2012, 31, 1931-1943.	0.8	12
131	Optimal design of multi‐arm multi‐stage trials. Statistics in Medicine, 2012, 31, 4269-4279.	0.8	85
132	Symmetric maximum kernel likelihood estimation. Journal of Statistical Computation and Simulation, 2011, 81, 193-206.	0.7	4
133	Estimation of pharmacokinetic parameters with the R package PK. Pharmaceutical Statistics, 2011, 10, 284-288.	0.7	60
134	A formal comparison of different methods for establishing cut points to distinguish positive and negative samples in immunoassays. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 1148-1156.	1.4	25
135	Probabilistic relabelling strategies for the label switching problem in Bayesian mixture models. Statistics and Computing, 2010, 20, 357-366.	0.8	65
136	Direct effects testing: A two‐stage procedure to test for effect size and variable importance for correlated binary predictors and a binary response. Statistics in Medicine, 2010, 29, 2544-2556.	0.8	3
137	Optimization, refinement and reduction of murine *in vivo* experiments to assess therapeutic approaches for haemophilia A. Laboratory Animals, 2010, 44, 211-217.	0.5	12
138	Establishing Bioequivalence in Complete and Incomplete Data Designs Using AUCs. Journal of Biopharmaceutical Statistics, 2010, 20, 803-820.	0.4	10
139	Recording Lectures as a Service in a Service Course. Journal of Statistics Education, 2009, 17, .	1.4	6
140	A Theoretical Framework for Estimation of AUCs in Complete and Incomplete Sampling Designs. Statistics in Biopharmaceutical Research, 2009, 1, 176-184.	0.6	30
141	A note on statistical analysis of organ weights in non-clinical toxicological studies. Toxicology and Applied Pharmacology, 2009, 240, 117-122.	1.3	25
142	Assessing Systemic Drug Exposure in Repeated Dose Toxicity Studies in the Case of Complete and Incomplete Sampling. Biometrical Journal, 2009, 51, 1017-1029.	0.6	9
143	Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs. Journal of Pharmacokinetics and Pharmacodynamics, 2009, 36, 479-494.	0.8	21
144	One‐and two‐stage design proposals for a phase II trial comparing three active treatments with control using an ordered categorical endpoint. Statistics in Medicine, 2009, 28, 828-847.	0.8	30

#	Article	IF	Citations
145	Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods. Pharmaceutical Statistics, 2009, 8, 12-24.	0.7	22
146	Assessing differential effects: Applying regression mixture models to identify variations in the influence of family resources on academic achievement.. Developmental Psychology, 2009, 45, 1298-1313.	1.2	73
147	Using a problem-based approach to teach statistics to postgraduate science students: A case study. MSOR Connections, 2009, 9, 40-47.	0.1	4
148	Maximum Kernel Likelihood Estimation. Journal of Computational and Graphical Statistics, 2008, 17, 976-993.	0.9	8
149	Using Multilevel Mixtures to Evaluate Intervention Effects in Group Randomized Trials. Multivariate Behavioral Research, 2008, 43, 289-326.	1.8	30
150	Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs. Journal of Pharmacokinetics and Pharmacodynamics, 2005, 32, 757-766.	0.8	24
151	Using biomarkers to allocate patients in a response-adaptive clinical trial. Communications in Statistics Part B: Simulation and Computation, 0, , 1-20.	0.6	0